Objectives: Azole-resistant Aspergillus fumigatus is emerging worldwide. Reference susceptibility testing methods are technically demanding and no validated commercial susceptibility tests for moulds currently exist. In this multicentre study a 4-well azole-containing screening agar method was evaluated using clinically relevant isolates.
Introduction
Resistance in Aspergillus fumigatus is emerging worldwide. 1, 2 The most common underlying mechanism is acquired alterations in the CYP51A target gene with or without concomitant tandem repeats in the promotor region of the gene. Acquired resistance has been associated with long-term azole exposure in patients with chronic forms of aspergillus disease. Such cases involve a whole range of different cyp51A mutations, among which the G54 and M220 codons are dominant targets, but in a subset of patients alternative non-cyp51A-related mechanisms or no mechanisms have been found. 1, [3] [4] [5] Moreover, mixed infections involving azolesusceptible and azole-resistant isolates concomitantly are regularly found. 6, 7 Azole-resistant A. fumigatus isolates have also been found in soil, compost, outdoor air and indoor environmental samples as well as in specimens from azole-exposed and azolenaive patients. [7] [8] [9] [10] [11] Recently a fatal case of invasive aspergillosis due to a resistant isolate was linked to the environment by subsequent isolation of isogenic resistant strains in the patient's home and garden, documenting the surroundings as source of an azoleresistant infection. 12 The most common resistance mechanisms found in azole-resistant environmental strains are the TR 34 /L98H alterations conferring pan-azole resistance and the TR 46 /Y121F/ T289A Cyp51A alterations conferring high-level voriconazole and isavuconazole resistance. 2, 7 An overall resistance rate of 3.2% was reported in an international survey covering 19 countries in 2009-11. 13 However, resistance rates were increasing in a recent Danish laboratory study, from 1.8% of the patients in 2010 to 4% patients in 2014, and were as high as 6.25% in Italy and 26% in an ICU in the Netherlands. [14] [15] [16] Against this background, antifungal susceptibility testing of clinically relevant A. fumigatus isolates appears mandatory.
Reference methods for the susceptibility testing of moulds have been established, i.e. the CLSI M38-A2 document and the EUCAST E.Def 9.3 document. 17, 18 Both methods are based on microbroth dilution with visual endpoint reading after 48 h, and when performed in mycology laboratories provide accurate and reproducible MIC results. The methods are, however, technically demanding and less attractive for the routine laboratory. No commercial MIC tests have been officially approved for Aspergillus susceptibility testing. Some studies have been conducted to evaluate the performance of Etest but with variable results. [19] [20] [21] [22] Consequently, antifungal susceptibility testing of moulds is often either not performed at all or delayed due to referral to a reference laboratory with a 5 day weekly service. In the absence of an easyto-use susceptibility test for A. fumigatus, an azole-containing agar screening multiwell plate was introduced in 2009 for the international A. fumigatus resistance prevalence study (the SCARE network). 13 This plate has since been adopted for various environmental studies and also for clinical testing although a systematic multicentre validation of its performance has not been undertaken. It is available commercially from VIPcheck, BovenLeeuwen, The Netherlands. Here, we systematically evaluate the performance of the azole-containing agar screening plate in a multicentre study using a molecularly characterized A. fumigatus strain collection with equal representation of WT isolates and of resistant mutants harbouring the four most common resistance mechanisms. Additionally, we investigated if a resistant mutant would be detected in a mixed WT and mutant A. fumigatus infection, testing the worst-case scenario that resistant colonies represent the minority of isolated colonies sampled together.
Materials and methods

Study design
A blinded set of well-characterized A. fumigatus isolates, in-house prepared plates and VIPcheck plates were sent to each of the participating laboratories. In each laboratory all plates were read blinded by two independent readers.
Aspergillus isolates
Thirty-nine molecularly characterized azole-resistant cyp51A mutant and 40 WT clinical A. fumigatus isolates were included. Species identification was performed by standard microbiological techniques, and A. fumigatus sensu stricto was confirmed by thermotolerance at 50 C. 23 The mutant strains harboured the following common molecular cyp51A azole resistance alterations: 10 with G54 mutations (4 G54E, 1 G54R, 1 G54R ! N248K, 1 G54V, 3 G54W), 10 with M220 mutations (2 M220I, 1 M220I ! V101F, 3 M220K, 2 M220T, 2 M220V), 9 with TR 34 /L98H alterations and 10 with TR 46 /Y121F/T289A alterations. CYP51A target gene sequencing was done as previously described. 8 
Susceptibility MIC testing
Itraconazole, posaconazole and voriconazole EUCAST MICs were determined according to the E.Def 9.3 reference standard and are presented by genotype in Table 1 . 18 Azole-containing agar plates Four-well multidish plates (Nunc V R IVF multidish, Sigma-Aldrich, The Netherlands) were prepared containing RPMI 1640-2% glucose agars supplemented with 4 mg/L itraconazole, 1 mg/L voriconazole, 0.5 mg/L posaconazole and no antifungal, respectively (in-house plates). In addition, plates with the same composition were purchased from VIPcheck, BovenLeeuwen, The Netherlands (commercial plates).
Assessment of screening method
Briefly, isolates were subcultured on Sabouraud-Chloramphenicol agar (Bio-Rad, Utrecht, The Netherlands; laboratories 2 and 3) or YGC agar (Oxoid PO5032A, Wessel, Germany; laboratory 1). Inoculum suspensions were prepared by touching the colonies from pure cultures with a moist swab and preparing a 0.5 McFarland solution in sterile water and then 25 lL was applied to each well of the two screening agar brands in parallel, starting in the upper left well and ending in the lower right drug-free control well. Plates were incubated at 35+2 C for 2 days and read by two independent readers if sufficient growth was seen in the control well (day 3 if insufficient growth). Growth was scored for each isolate and well (itraconazole, voriconazole, posaconazole and control well) as follows: 0, no visible growth; 1, weak growth where the agar has been inoculated; 2, growth but less than on the control agar; 3, uninhibited growth, similar to that in the control well. Laboratory 2 failed to test one of the WT isolates (strain 32), generating a total of 3788 scores.
Test of the 'pick five colonies' recommendation 24, 25 Inoculum suspensions were prepared from simulated mixed WT and mutant specimens using pure cultures of WT, G54W and TR 34 /L98H A. fumigatus isolates. Fresh 2-4 day culture plates were prepared for each of the three strains above for each repetition. Then, the WT colony was touched four times and the mutant colony once with a single moist swab and subsequently used to prepare a 0.5 McFarland inoculum solution in sterile water (laboratories 1 and 2), whereas the same procedure was performed in the third laboratory except using an individual moist swab for each colony touch (five per inoculum suspension mixture). This procedure was performed three times for the WT/G54W combination and three times for the WT/TR 34 /L98H combination on three separate days along with each of the two mutant strains alone for comparison and control.
Data management
Inter-observer and inter-plate quantitative agreement (score differences 0, 1 or 2) and qualitative (0 versus .0) were calculated and presented as median and ranges (among the three laboratories) for each of the azoles (itraconazole, voriconazole, posaconazole and drug-free control). The quantitative agreement was evaluated as identical scores (score difference 0), one score step difference or two score step differences.
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For the qualitative agreement, an agreement was considered when the scores for the two readers and plate brands were either 0 or any other score .0. Qualitative global inter-observer agreement among the three laboratories was determined for each plate brand, azole and score (using scores of .0, .1 and .2 for categorizing as screening positive or negative). Finally, the overall performance of the 4-well plates was evaluated by calculating sensitivity/specificity based on the presence of cyp51A mutations and growth (score .0 and for score .1) in at least one azolecontaining agar well by laboratory and by cyp51A alteration.
Results
EUCAST susceptibility pattern by Cyp51A alteration
To confirm the association between the phenotypic susceptibility of the strains tested and their genetic background, isolates were EUCAST susceptibility tested independently of performing the screening test (Table 1) . G54 alterations were universally associated with resistance to itraconazole and posaconazole but not to voriconazole, M220 alterations were also associated with resistance to itraconazole and posaconazole and with variable voriconazole susceptibility, except M220T which was susceptible to posaconazole and voriconazole. TR 34 /L98H alterations were associated with pan-azole resistance and TR 46 /Y121F/T289A with highlevel voriconazole resistance but with variable itraconazole and posaconazole susceptibility.
Growth characteristics on azole-containing agar plates
All isolates grew well on the drug-free control agar with score 3 for the vast majority of the isolates (99%) and score 2 for the remaining ones (Figure 1) . In contrast, all WT isolates either failed to grow on the azole-containing agars (score 0) or, in a minority of cases (1%), displayed weak growth on the itraconazole-containing agar only (score 1). cyp51A mutant isolates exhibited a cyp51A genotype and antifungal compound dependent differential growth pattern (Figure 1) . The individual performance of the azole-containing agars to separate WT and mutant isolates were first evaluated. The itraconazole-containing agar identified the vast majority of the mutant isolates, including all G54 mutants (with scores 2-3), 97% of the M220 and TR 34 /L98H mutants but only 55% of the TR 46 /Y121F/T289A mutants ( Figure 1 ). In contrast, the voriconazole-containing agar identified all but 1% of the TR 46 /Y121F/T289A mutants, whereas 9% TR 34 /L98H, 76% M220 and almost all (97%) G54 mutants failed to grow. Finally, the posaconazole-containing agar identified the majority of G54 and M220 mutants although only half with a score 2, whereas the detection of the environmental mutants TR 34 /L98H and TR 46 /Y121F/ T289A was much less reliable (no growth for 44% and 73%, respectively) (Figure 1 ).
Inter-observer and inter-plate agreement
Next, the inter-observer agreement was determined for the two plates. The percentage of identical scores varied between 80% and 100% with a median percentage of 87%-99% for the commercial plates and 86%-99% for the in-house plates across all isolates (Table S1 , available as Supplementary data at JAC Online). The agreement was best for the WT isolates where the median percentage identical scores were 98%-100% and in no case was a difference in score of .1 observed. For the cyp51A mutant strains the agreement was slightly lower, mainly driven by a lower agreement for itraconazole for which median identical scores were found for 77% (59%-77%) for the commercial plates and 74% (62%-74%) for the in-house plates. The qualitative agreement [no growth (0) versus growth (.0)] was excellent (median 95%-100% overall). It was slightly lower for the cyp51 mutants with median (range) varying between 92% (87%-97%) for the voriconazolecontaining agar to 100% (100%-100%) for the drug-free control for the commercial plates and 90% (87%-95%) for the posaconazole-containing agar to 100% (100%-100%) for the drug-free control for the in-house plates. The inter-plate agreement was similarly high for both observers and with the same Screening method for azole-resistant A. fumigatus JAC pattern, i.e. highest for the WT isolates and for the drug-free growth control and slightly lower for the cyp51A mutants particularly with itraconazole ( Table 2) .
The qualitative inter-observer agreement for three cutoff criteria (score 0 versus .0; 1 versus .1; and 2 versus .2) was next determined (Table S2) . Overall, the best agreement was found for the 1 versus .1 criteria independent of which plate was used (88%-100% for the commercial plates and 90-100% for the inhouse plates), and again best agreement was found for the WT isolates 98%-100%. However, for voriconazole specifically the best agreement was found for the 2 versus .2 criteria (95% for both plates), although this overall was the poorest performing criterion (68%-97%) and particularly so for the cyp51A mutants (38%-95%).
Sensitivity and specificity
The overall performance of the 4-well screening plates was evaluated with respect to the sensitivity and specificity to differentiate between cyp51A mutant and WT isolates based on a score .0 Arendrup et al. (Table 3) or .1 (Table 4) in at least one of the three azolecontaining agars (and the positive growth control). One mutant harbouring the M220T alteration was missed in laboratory 1 across both observers and plates. Thus, the overall sensitivity and specificity for the 4-well screening agar plate and the 0 versus .0 criteria was 99% (range 97%-100%) and 99% (95%-100%), respectively. The performance of the azole-containing agars in pairs was also evaluated and remained unchanged using only itraconazole-and voriconazole-containing agars, but lower for the other combinations (Table 3 ). Adopting the score 1 versus .1 instead, the overall performance of the 4-well plate was similar with a mean sensitivity slightly lower at 97.5% (range 97%-98%) and a mean specificity slightly higher at 99.75% (99%-100%) (Table S3 ).
'Pick five colonies'
Finally, detection of cyp51A mutant A. fumigatus in a simulated mix of WT and mutant colonies was investigated ( Table 4) . The WT/G54W mixed specimens were correctly identified by all three laboratories independently of whether one swab was used (laboratories 1 and 2) or five individual swabs were used (laboratory 3) for sampling (Table 4 ). In detail, no decrease in the average growth score or proportion of growth-positive agars was observed for any of the three azoles for this strain combination. However, when the WT/TR 34 /L98H combination was examined, the average growth score decreased for itraconazole (from 1.6 to 0.7 in laboratory 1, and from 2.3 to 1.3 in laboratory 2) but not in the laboratory using individual swabs for each colony touch (laboratory 3). Similarly, the average growth score decreased for the voriconazole well in laboratory 1 (from 0.6 to 0.1). Overall, this resulted in a sensitivity for the WT/TR 34 /L98H combination of 94% (range 83%-100%), but an overall sensitivity for the WT/G54W combination of 100%. This performance was unchanged if only the growth in itraconazole and voriconazole wells were evaluated. Finally, the specificity was unchanged (100%) for the WT/mutant mixed specimens.
Discussion
In the setting of a worldwide increase in azole resistance in A. fumigatus among azole-naive as well as azole-exposed patients, rapid, laboratory-friendly and reliable detection of resistant isolates is crucial. 2 In this study, we demonstrated excellent performance by a 4-well azole-containing agar screening plate for correct identification of resistant mutants. Across in-house and commercial plates, three laboratories and six observers, only a single mutant was incorrectly categorized as susceptible in one of the three laboratories, leading to an overall sensitivity and specificity of 99%. This specific mutant harboured the M220T alteration and demon- In-house plates, observer 1 Commercial plates, observer 2 In-house plates, observer 2 sensitivity (%) specificity (%) sensitivity (%) specificity (%) sensitivity (%) specificity (%) sensitivity (%) specificity (%) Itraconazole/posaconazole  laboratory 1  79  100  82  100  82  100  82  98  laboratory 2  90  100  92  95  87  100  95  98  laboratory 3  95  98  90  100  92  100  90  100  overall  88  99  88  98  87  100  89  98  Voriconazole/posaconazole  laboratory 1  67  100  67  100  77  100  77  100  laboratory 2  92  100  92  100  95  100  95  100  laboratory 3  95  98  95  100  95  100  92  100  overall  85  99  85  100  89  100  88  100 Performance characteristics across the three laboratories are shown in bold, and performance values ,90% are underlined.
Screening method for azole-resistant A. fumigatus JAC Table 4 . Growth scores and sensitivity for combined testing of four WT and one mutant colonies Growth (score .0) was required for positivity. Sensitivity was determined for each azole-containing agar individually, for itraconazole/voriconazole/posaconazole and itraconazole/ voriconazole only in all cases requiring at least one positive azole-containing agar. Two laboratories (one in Germany and one in Belgium) used a single moist swab for sampling the WT four times followed by the mutant once, whereas one laboratory (in the Netherlands) used five individual moist swabs (one for each colony sampling) for inoculum preparation. Performance characteristics across the three laboratories are shown in bold.
Arendrup et al. 30 found the opposite. The underlying reasons for the discrepancies are unclear, but variation in media composition and height, inoculum size, incubation time and conditions, and inhibition zone definition and subjectivity in endpoint reading are all factors that may influence reproducibility across various laboratories. Moreover, only one of these studies included non-WT isolates (two itraconazoleresistant reference strains), and thus the performance with respect to reliable detection of resistance is not fully validated. In contrast, the isavuconazole Liofilchem strip was evaluated for a molecularly characterized strain collection of WT and mutant isolates and found useful for the correct separation of TR 34 /L98H and TR 46 /Y121F/T289A from WT A. fumigatus isolates, whereas the identification of G54 and M220 mutants was unreliable, in agreement with the fact that these mutations do not confer resistance to this compound. 21 The Sensititre Yeast One panel has also been compared with CLSI methods for various moulds. 22, 26, [31] [32] [33] [34] Although some variation was observed, the agreement was overall promising; however, resistant mutants were not evaluated in these studies either. Taken together, these studies on gradient strips and Sensititre for A. fumigatus MIC testing emphasize that performance may be variable among laboratories, suggesting the need for in-house validation before implementation, and that validation of the ability to detect resistant mutants for all three azoles is largely lacking. 26 Introducing the 4-well plate into routine clinical laboratories may have significant impact. Firstly, the most profound effect is that azole resistance will be reliably detected much earlier than is currently possible, and the individual patient will therefore benefit from more appropriate therapy. Timing of appropriate therapy is crucial. This has been demonstrated by the systematically superior outcome for patients in whom therapy is initiated early (indicated by the halo sign at chest CT). 35 Moreover, the outcome for patients treated with voriconazole when infected with resistant isolates is consistently poor. 7, 15, [36] [37] [38] Therefore, rapid detection of cases involving azole-resistant Aspergillus is the only tool allowing appropriate therapy both for resistant infection but also for susceptible infections where voriconazole is superior. 35, [39] [40] [41] [42] [43] [44] [45] Secondly, because more laboratories will be in the position to screen for azole resistance, more resistance may be detected. This in turn will have implications for the epidemiology of azole resistance, in particular in areas were screening is not common.
Our study has limitations. We included the most common resistance genotypes, which accounted for 74% of resistant A. fumigatus in the global SCARE study and 94% if the Manchester (UK) centre for chronic aspergillosis is excluded. 13 Hence, our study fails to provide information regarding detection of azole resistance due to alternative mechanisms. However, in the SCARE study the azole agar detected four other genotypes (F46/M172G, P38I/ D481E, L329I, L77V/L399I/D481E) as well as 13 azole-resistant sibling species. In addition, F219I, P216L, Y431C, G432S and a number of non-cyp51A-related azole-resistant strains have been detected using the screening agar in our and other laboratories, most of which are reported previously. 14, 46 These findings suggest the performance is not limited to the included cyp51A genotypes. However, further studies are warranted, particularly for mutants associated with low-grade MIC elevation.
We demonstrate here excellent sensitivity and specificity parameters when testing WT and mutant pure cultures. We also demonstrate that mutants will be reliably detected if adopting the 'pick five colonies' strategy in the vast majority of cases even in the ratio of 1:5 and even if only using a single swab for sampling the colonies. We believe introduction of these screening plates into clinical microbiology laboratories serving patients at risk of invasive aspergillus disease or requiring treatment for chronic forms of aspergillus disease would help to ensure timely and appropriate therapy.
